Tarsus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Tarsus Pharmaceuticals has a total shareholder equity of $237.5M and total debt of $71.7M, which brings its debt-to-equity ratio to 30.2%. Its total assets and total liabilities are $376.3M and $138.8M respectively.
Key information
30.2%
Debt to equity ratio
US$71.71m
Debt
| Interest coverage ratio | n/a |
| Cash | US$316.95m |
| Equity | US$237.48m |
| Total liabilities | US$138.82m |
| Total assets | US$376.30m |
Recent financial health updates
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28Recent updates
US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable
Sep 05Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Aug 20With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Financial Position Analysis
Short Term Liabilities: TARS's short term assets ($357.1M) exceed its short term liabilities ($65.9M).
Long Term Liabilities: TARS's short term assets ($357.1M) exceed its long term liabilities ($72.9M).
Debt to Equity History and Analysis
Debt Level: TARS has more cash than its total debt.
Reducing Debt: TARS's debt to equity ratio has increased from 0.3% to 30.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TARS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TARS has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 56.1% each year.